Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer

Current Medical Research and Opinion

Volumn 22, Issue 8, 2006, Pages 1575-1585

  Buzdar, Aman ^a   Chlebowski, Rowan ^b   Cuzick, Jack ^c   Duffy, Sean ^d   Forbes, John ^e   Jonat, Walter ^f   Ravdin, Peter ^g  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e UNIVERSITY OF NEWCASTLE   (Australia)

^f UNIVERSITY OF KIEL   (Germany)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Adjuvant; Aromatase; Breast cancer; Oestrogen; Postmenopausal; Switching; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; PLACEBO; TAMOXIFEN; TAMOXIFEN CITRATE; ZOLEDRONIC ACID;

ADJUVANT THERAPY; BREAST CANCER; CANCER PREVENTION; CANCER RECURRENCE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; EARLY CANCER; ENDOMETRIUM CANCER; ENDOMETRIUM POLYP; FRACTURE; GYNECOLOGIC DISEASE; HEALTH CARE ORGANIZATION; HEART DEATH; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW; STROKE; SYSTEMATIC REVIEW; TREATMENT DURATION; VAGINA BLEEDING; VAGINA DISCHARGE;

EID: 33748036987     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X120940     Document Type: Review

References (46)

1. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2
2. Thurlimann B, Keshaviah A, Coates A, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57
3. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 2005;23:5138-47
4. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92
5. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-62
6. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802
7. Jakesz R, Samonigg H, Greil R, et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-Ga). J Clin Oncol 2005;23:10s [abstract 527]
8. Voogd AC, van Oost FJ, Rutgers EJ, et al. Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J Cancer 2005;41:2637-44
9. Willner J, Kiricuta IC, Kolbl O, et al. Long-term survival following postmastectomy locoregional recurrence of breast cancer. Breast 1999;8:200-4
10. Buzdar AU, Blumenschein GR, Smith TL, et al. Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). J Surg Oncol 1979;12:27-40
11. Fortin A, Larochelle M, Laverdiere J, et al. Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. J Clin Oncol 1999;17:101-9
12. Lamerato L, Havstad S, Gandhi A, et al. Costs of initial, continuing and terminal care in US patients with recurrence following early breast cancer. J Clin Oncol 2005;23:37s [abstract 634]
13. Houghton J: ATAC Trialists' Group. Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events: updated data from the ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial. J Clin Oncol 2005;23:24s [abstract]
14. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14:2738-46
15. Jakesz R, Gnant M, Greil R, et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8. Breast Cancer Res Treat 2005;94:S10 [abstract 13]
16. Punglia RS, Kuntz KM, Winer EP, et al. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol 2005;23:5178-87
17. Buzdar AU, Cuzick J. Optimum use of aromatase inhibitors in the adjuvant treatment of early breast cancer. J Clin Oncol 2005;23:8544-6
18. Cuzick J, Sasieni P, Howell A. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer 2006;94:460-4
19. Viale G, Regan M, Dell'Orto B, et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat 2005;94:S13 [abstract 44]
20. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717
21. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93:684-90
22. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9
23. Dowsett M, Cuzick J, Wale C, et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005;23:7512-7
24. Cuzick J. Forest plots and the interpretation of subgroups. Lancet 2005;365:1308
25. Duffy SR, Distler W, on behalf of the ATAC Trialists' Group. Gynecologic interventions during adjuvant therapy with anastrozole or tamoxifen: results from the ATAC trial. Breast Cancer Res Treat 2005;94:S102 [abstract 2056]
26. Goss PE, Ingle JN, Palmer MJ, et al. Updated analysis of NCIC CTG MA 17 (letrozole vs placebo to letrozole vs placebo) post unblinding. Breast Cancer Res Treat 2005;94(Suppl 1):S10-11 [abstract 16]
27. Ismail AA, Pye SR, Cockerill WC, et al. Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study. Osteoporos Int 2002;13:565-71
28. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-57
29. Howell A, on behalf of the ATAC Trialists' Group. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial in post-menopausal women with early breast cancer - updated efficacy results based on a median follow-up of 5 years [online]. Available from http://209.196.53.174/2004 [Last accessed June 2006]
30. World Health Organization. Technical report series 843. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: WHO Press, 1994. Available from http://www.who.int/bookorders/anglais/ detart1.jsp?sesslan=1&codlan=1 &codcol=10&codcch=843# [Last accessed June 2006]
31. Eastell R. Effect of anastrozole of bone mineral density: 2 year results of the Arimidex (anastrozole) Tamoxifen, Alone or in combination (ATAC) trial. American Society for Bone and Mineral Research 25th Annual Meeting, Minneapolis, Minnesota, USA, 19-23 September 2003
32. Chlebowski RT. Bone health in women with early-stage breast cancer. Clin Breast Cancer 2005;5:S35-40
33. Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z-FAST update. Semin Oncol 2006;33:13-7
34. Garber JE, Halabi S, Kaplan E, et al. Factor V Leiden (FVL) mutations and thromboembolic events (TE) in women with breast cancer on adjuvant tamoxifen. Proc ASCO 2005;23:6s [abstract 508]
35. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34
36. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
37. Cushman M, Costantino JP, Tracy RP, et al. Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol 2001;21:255-61
38. Bagdade JD, Wolter J, Subbaiah PV, et al. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab 1990;70:1132-5
39. Sawada S, Sato K, Kusuhara M, et al. Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer. Acta Oncol 2005;44:134-41
40. McCloskey E, Eastell R, Lakner G, et al. Initial results from the LEAP study: the first direct comparison of safety parameters between aromatase inhibitors in healthy postmenopausal women. Breast Cancer Res Treat 2005;94:S101 [abstract 2052]
41. Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18:937-47
42. Howell A, on behalf of the ATAC Trialists' Group. ATAC trial update - authors' reply. Lancet 2005;365:1225-6
43. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA 17. J Natl Cancer Inst 2005;97:1262-71
44. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88
45. Duggan C, Marriott K, Edwards R, et al. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol 2003;21:3588-93
46. Howell A. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial in postmenopausal women with early breast cancer - updated efficacy results based on a median follow-up of 5 years. Breast Cancer Res Treat 2004;88 (Suppl 1):S7 [abstract 1]